EFFECT ·Filed Sep 4, 2026

ONCO

Onconetix, Inc.
BEARISH
Impact 8/10
Horizonimmediate Processed28d 10h ago SEC9999999995-26-002880
IPO/offering going effective
Actionable Insight ▼ Bearish

The effectiveness opens the door for immediate resale by Seven Knots LLC. Expect heavy selling pressure and further price deterioration. Traders should avoid long positions and consider short exposure given the extreme dilution risk and going concern status.

DirectionBearish
Confidencehigh
Horizonimmediate
Latest settled — T+5d ⚠ clustered
ONCO ▼ -37.51% at T+5d
SHORT call ✓ call won +37.51% · α vs SPY +36.30% · entry $1.02 → $0.6374
Next anchor: T+20d in 2d
Latest observation: T+18 +32.74% FF3 residual α
Entry anchored
Sep 3, 07:06 PM ET
via 1-min bar
T+1d
-17.65%
call +17.65% · α +17.10%
$0.8400
settled 25d ago
T+5d
-37.51%
call +37.51% · α +36.30%
$0.6374
settled 19d ago
T+20d
—
call — · α —
—
in 2d
T+60d
—
call — · α —
—
in 8w

Price Chart

Loading chart...

Executive Summary

Onconetix's S-1 registration (File No. 333-298259) became effective on September 3, 2026, enabling the resale of up to 100,000,000 shares by Seven Knots LLC. This represents approximately 2,282% dilution of current outstanding shares, in a company with a going concern warning and minimal cash. The effectiveness is the final procedural step before potential immediate selling, which will likely crush the stock price.

Key Facts

  • S-1 registration effective 2026-09-03 for resale of up to 100,000,000 shares by Seven Knots LLC
  • Shares represent ~2,282% of current outstanding shares (per prior S-1/A filing)
  • Company has a going concern warning and minimal cash ($5.1M as of Aug 28, 2026)
  • Market cap is only ~$3M, making dilution potentially catastrophic

Financial Impact

Potential dilution of up to 100M shares vs ~4.4M current outstanding (per prior filing), representing over 20x dilution. No new cash raised for the company.

dilutionshare countmarket cap

Risk Factors

  • Immediate dilutive selling by Seven Knots could drive the stock to near zero
  • Company may require further dilutive financing to stay afloat
  • Potential delisting from Nasdaq due to low market cap and share price

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002880
Document: 9999999995-26-002880-index.html9999999995-26-002880
Document: 9999999995-26-002880.txt9999999995-26-002880
22 reports for ONCO
Performance horizon
64% Hit rate 7 of 11 directional calls best @ T+60▲ +78.04%May 8, 2026
Filters
Rows
Reports for ONCO — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
DEFA14A / 8-K
NEUTRAL ★ 4/10
$0.6374 $0.6549▲ +2.75%▲ +2.64%$0.7440 (+16.72%)
Sep 14, 2026
18d ago
8-K
BEARISH ★ 6/10
$0.6374 $0.6549▼ −2.75%▼ −2.64%$0.7440 (−16.72%)
Sep 14, 2026
18d ago
425
BEARISH ★ 6/10
$0.6374 $0.6549▼ −2.75%▼ −2.64%$0.7440 (−16.72%)
Sep 4, 2026
28d ago
EFFECT
BEARISH ★ 8/10
$1.02 $0.6374▲ +37.51%▲ +36.30%$0.7440 (+27.06%)
Sep 3, 2026
29d ago
425
NEUTRAL ★ 3/10
$0.7390 $0.7564▲ +2.35%▲ +3.50%$0.7440 (+0.68%)
Aug 31, 2026
4w ago
S-1/A
BEARISH ★ 8/10
$0.6528 $0.8132▼ −24.57%▼ −24.49%$0.7440 (−13.97%)
Aug 12, 2026
7w ago
S-1
BEARISH ★ 8/10
$0.8920 $0.7110▲ +20.29%▲ +19.85%$0.7440 (+16.59%)
Jul 29, 2026
9w ago
8-K
BEARISH ★ 8/10
$0.7864 $0.9037▼ −14.92%▼ −11.29%$0.7440 (+5.39%)
Jul 7, 2026
12w ago
425
NEUTRAL ★ 2/10
$1.07 $0.8487▼ −20.68%▼ −21.23%$0.7440 (−30.47%)
Jun 17, 2026
15w ago
EFFECT
BEARISH ★ 6/10
$0.9949 $1.00▼ −0.51%▼ −1.55%$0.7440 (+25.22%)
Showing 10 of 22

US Market Status

Market Closed — Opens Mon (37h 29m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access